PATENT CLAIM ANALYSIS

Application Number: 16034064
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "130100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Claim (Index 18):
The method of  claim 1 , wherein the RAR\u03b3 agonist is a RAR\u03b3 selective agonist selected from CD437, CD2325, CD666, and BMS961.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 95.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16034123', '15868469', '15620411', '15868450', '15868459']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8110906738089521
- 35 USC 102 Novelty (BERT): 0.6561614399923741
- Combined Prediction Score: 0.7955977504272943
- Mean Citation Score: 524.742364
- Max Citation Score: 660.15515
- Similarity Product: 647.6353823987067

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test